NEW DELHI New Delhi: Biological therapies are revolutionizing severe asthma management, increasing the possibility of asthma cure, but cost and equitable access remain major hurdles, according to a report on Tuesday. Biological therapy, also known as immunotherapy, is a type of treatment that uses substances derived from living organisms to treat disease.
Data and analytics company GlobalData reports that new biologics target specific inflammatory pathways, shifting care from symptom control to potential remission.Dupilumab interleukin-4 receptor alpha and tezepelumab (anti-thymic stromal Biologic therapies such as lymphopoietin (TSLP) show potential for widespread application. They also provide benefits to patients with different inflammatory profiles.
According to real-world evidence, these treatments have proven their efficacy in diverse patient profiles, including patients with complex asthma cases. However, reports cite barriers such as cost and access. It stressed the urgent need for equitable healthcare solutions to ensure widespread adoption of these transformative treatments.
“Biologics have fundamentally changed our approach to severe asthma by enabling targeted, personalized treatments, but access is still needed to realize their full potential,” said Shravani Meka, senior pharmaceutical (TADAWUL:2070) analyst at GlobalData. It is important to expand.” Meka said, “The long-term impact of these treatments will shift asthma management from simply controlling symptoms to achieving remission, similar to the progress seen in areas such as rheumatoid arthritis. May go.”
While biologics have shown great promise, barriers such as cost, access, and insurance coverage limit their availability, particularly in underserved communities. This is further complicated by environmental and social factors. Many patients in high-risk areas are disproportionately exposed to pollutants that worsen symptoms.
“Even in patients with low eosinophil (a type of white blood cell that helps fight infection) counts, tezepelumab has broad efficacy in treating asthma across a variety of profiles and patient demographics,” Meka said. “Highlights the potential of biologics.” Systemic changes are important to improve healthcare equity and access, even as efforts to expand access to biologics in the treatment of severe asthma are underway However, Meka called for “continued attention to cost and access issues”. He said this would ensure that biologics are available to all patients who need them.
Comments are closed.